TRIDENT Phase 3 Trial (EF-32): First-line Tumor Treating Fields (TTFields; 200 kHz) Concomitant With Chemo-radiation, Followed by Maintenance TTFields/Temozolomide in Newly-diagnosed Glioblastoma